JP2014521652A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014521652A5 JP2014521652A5 JP2014522997A JP2014522997A JP2014521652A5 JP 2014521652 A5 JP2014521652 A5 JP 2014521652A5 JP 2014522997 A JP2014522997 A JP 2014522997A JP 2014522997 A JP2014522997 A JP 2014522997A JP 2014521652 A5 JP2014521652 A5 JP 2014521652A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- nitrogen
- sulfur
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 65
- 150000001875 compounds Chemical class 0.000 claims 58
- 229910052757 nitrogen Inorganic materials 0.000 claims 50
- 229910052760 oxygen Inorganic materials 0.000 claims 34
- 229910052717 sulfur Inorganic materials 0.000 claims 33
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 32
- 239000001301 oxygen Substances 0.000 claims 32
- 125000005842 heteroatom Chemical group 0.000 claims 31
- 239000011593 sulfur Substances 0.000 claims 31
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 29
- 229910052736 halogen Inorganic materials 0.000 claims 24
- 150000002367 halogens Chemical class 0.000 claims 24
- 229920006395 saturated elastomer Polymers 0.000 claims 22
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 239000001257 hydrogen Substances 0.000 claims 18
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 17
- 125000000623 heterocyclic group Chemical group 0.000 claims 15
- 238000000034 method Methods 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 9
- 230000000269 nucleophilic effect Effects 0.000 claims 9
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical group C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- -1 4-hydroxypiperidin-1-yl Chemical group 0.000 claims 6
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims 6
- 125000001931 aliphatic group Chemical group 0.000 claims 6
- 229910052805 deuterium Inorganic materials 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 6
- 229910052722 tritium Inorganic materials 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 claims 3
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims 2
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- XULIXFLCVXWHRF-UHFFFAOYSA-N 1,2,2,6,6-pentamethylpiperidine Chemical compound CN1C(C)(C)CCCC1(C)C XULIXFLCVXWHRF-UHFFFAOYSA-N 0.000 claims 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- HVHZEKKZMFRULH-UHFFFAOYSA-N 2,6-ditert-butyl-4-methylpyridine Chemical compound CC1=CC(C(C)(C)C)=NC(C(C)(C)C)=C1 HVHZEKKZMFRULH-UHFFFAOYSA-N 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 101100004408 Arabidopsis thaliana BIG gene Proteins 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 239000004215 Carbon black (E152) Substances 0.000 claims 1
- 101100485279 Drosophila melanogaster emb gene Proteins 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 102100029095 Exportin-1 Human genes 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- GSCCALZHGUWNJW-UHFFFAOYSA-N N-Cyclohexyl-N-methylcyclohexanamine Chemical compound C1CCCCC1N(C)C1CCCCC1 GSCCALZHGUWNJW-UHFFFAOYSA-N 0.000 claims 1
- 101100485284 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CRM1 gene Proteins 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 101150094313 XPO1 gene Proteins 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- UURSXESKOOOTOV-UHFFFAOYSA-N dec-5-ene Chemical compound CCCCC=CCCCC UURSXESKOOOTOV-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108700002148 exportin 1 Proteins 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 235000012631 food intake Nutrition 0.000 claims 1
- 208000037824 growth disorder Diseases 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 229930195733 hydrocarbon Natural products 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 125000004262 quinoxalin-2-yl group Chemical group [H]C1=NC2=C([H])C([H])=C([H])C([H])=C2N=C1* 0.000 claims 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 230000008467 tissue growth Effects 0.000 claims 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161513428P | 2011-07-29 | 2011-07-29 | |
| US201161513432P | 2011-07-29 | 2011-07-29 | |
| US61/513,432 | 2011-07-29 | ||
| US61/513,428 | 2011-07-29 | ||
| US201261610178P | 2012-03-13 | 2012-03-13 | |
| US61/610,178 | 2012-03-13 | ||
| US201261653588P | 2012-05-31 | 2012-05-31 | |
| US61/653,588 | 2012-05-31 | ||
| US201261654651P | 2012-06-01 | 2012-06-01 | |
| US61/654,651 | 2012-06-01 | ||
| PCT/US2012/048319 WO2013019548A1 (en) | 2011-07-29 | 2012-07-26 | Hydrazide containing nuclear transport modulators and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016174614A Division JP6309057B2 (ja) | 2011-07-29 | 2016-09-07 | ヒドラジド含有核輸送調節因子およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014521652A JP2014521652A (ja) | 2014-08-28 |
| JP2014521652A5 true JP2014521652A5 (https=) | 2015-08-20 |
| JP6005740B2 JP6005740B2 (ja) | 2016-10-12 |
Family
ID=46634546
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014522997A Active JP6005740B2 (ja) | 2011-07-29 | 2012-07-26 | ヒドラジド含有核輸送調節因子およびその使用 |
| JP2016174614A Active JP6309057B2 (ja) | 2011-07-29 | 2016-09-07 | ヒドラジド含有核輸送調節因子およびその使用 |
| JP2018044974A Active JP6675431B2 (ja) | 2011-07-29 | 2018-03-13 | ヒドラジド含有核輸送調節因子およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016174614A Active JP6309057B2 (ja) | 2011-07-29 | 2016-09-07 | ヒドラジド含有核輸送調節因子およびその使用 |
| JP2018044974A Active JP6675431B2 (ja) | 2011-07-29 | 2018-03-13 | ヒドラジド含有核輸送調節因子およびその使用 |
Country Status (35)
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103002742B (zh) | 2010-03-05 | 2016-07-13 | 卡尔约药物治疗公司 | 核转运调节剂及其应用 |
| JP6106605B2 (ja) | 2011-01-17 | 2017-04-05 | カリオファーム セラピューティクス，インコーポレイテッド | オレフィン含有核輸送調節剤およびその使用 |
| SMT201800171T1 (it) * | 2011-07-29 | 2018-07-17 | Karyopharm Therapeutics Inc | Modulatori di trasporto nucleare contenenti idrazide e loro usi |
| US9428490B2 (en) * | 2011-07-29 | 2016-08-30 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| WO2013109057A1 (ko) | 2012-01-18 | 2013-07-25 | (주)바이오니아 | 자성나노입자-samirna 복합체 및 그 제조방법 |
| CA2872190C (en) | 2012-05-09 | 2024-06-25 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| CN105073728A (zh) | 2013-03-15 | 2015-11-18 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
| US10202366B2 (en) * | 2013-03-15 | 2019-02-12 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using CRM1 inhibitors |
| WO2014205393A1 (en) * | 2013-06-21 | 2014-12-24 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| DK3492455T3 (da) | 2013-06-21 | 2023-08-14 | Karyopharm Therapeutics Inc | 1,2,4-triazoler som nukleare transportmodulatorer og anvendelse til behandling af specifikke former for cancer |
| US9695421B2 (en) | 2013-07-05 | 2017-07-04 | Bioneer Corporation | Dengue virus-specific siRNA, double helix oligo-RNA structure comprising siRNA, and composition for suppressing proliferation of dengue virus comprising RNA structure |
| CN105705638B (zh) | 2013-07-05 | 2019-11-26 | 柏业公司 | 改善的具有高效能的纳米颗粒型寡核苷酸结构及其制备方法 |
| KR20150006743A (ko) * | 2013-07-09 | 2015-01-19 | (주)바이오니아 | 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물 |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| US9861615B2 (en) * | 2013-11-28 | 2018-01-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of beta-thalassemias |
| CN106459974A (zh) | 2014-04-04 | 2017-02-22 | 柏业公司 | 新颖的双链寡rna和包含它的用于预防或治疗纤维化或呼吸系统疾病的药物组合物 |
| CN111484483B (zh) * | 2014-08-15 | 2023-05-26 | 卡尔约药物治疗公司 | 赛灵克斯的多晶型物 |
| US10526295B2 (en) | 2015-12-31 | 2020-01-07 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| WO2017117535A1 (en) | 2015-12-31 | 2017-07-06 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| WO2017118940A1 (en) * | 2016-01-08 | 2017-07-13 | Dr. Reddy's Laboratories Limited | Solid forms of selinexor and process for their preparation |
| EP3241830A1 (de) | 2016-05-04 | 2017-11-08 | Bayer CropScience Aktiengesellschaft | Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel |
| US11065230B2 (en) | 2016-09-16 | 2021-07-20 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of systemic mastocytosis |
| US11602530B2 (en) | 2016-11-28 | 2023-03-14 | Biogen Ma Inc. | CRM1 inhibitors for treating epilepsy |
| WO2018129227A1 (en) | 2017-01-05 | 2018-07-12 | Watson Laboratories Inc. | Novel crystalline forms of selinexor and process for their preparation |
| CN106831731B (zh) * | 2017-01-17 | 2019-11-08 | 广州市闻皓生物科技有限公司 | 一种Selinexor原料药的合成方法 |
| CN106831617A (zh) * | 2017-01-17 | 2017-06-13 | 广州市闻皓生物科技有限公司 | 一种Selinexor中间体的合成工艺 |
| WO2018191707A2 (en) * | 2017-04-13 | 2018-10-18 | Brown University | Nucleocytoplasmic regulator of autophagy-associated transcription factors |
| WO2019232724A1 (en) | 2018-06-06 | 2019-12-12 | Xw Laboratories, Inc. | Compounds as nuclear transport modulators and uses thereof |
| CN108947982A (zh) * | 2018-08-16 | 2018-12-07 | 刘璐 | 治疗非酒精性脂肪肝病的吡嗪衍生物、组合物和应用 |
| WO2020092965A1 (en) * | 2018-11-01 | 2020-05-07 | Karyopharm Therapeutics Inc. | E2f1 as a biomarker for treatments using xpo1 inhibitors |
| CN111606890A (zh) * | 2019-02-26 | 2020-09-01 | 微境生物医药科技(上海)有限公司 | 含丙烯酰基的核转运调节剂及其用途 |
| CA3130107A1 (en) | 2019-03-20 | 2020-09-24 | Johnson Matthey Public Limited Company | Co-crystal forms of selinexor |
| GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
| KR20220004142A (ko) | 2019-05-01 | 2022-01-11 | 카리오팜 쎄라퓨틱스, 인코포레이티드 | Xp01 억제제 및 xp01 억제제의 제조에 사용하기 위한 중간체의 제조 방법 |
| EP3808742A1 (en) | 2019-10-16 | 2021-04-21 | Sandoz AG | Polymorph of selinexor |
| WO2021163338A1 (en) | 2020-02-11 | 2021-08-19 | Karyopharm Therapeutics Inc. | Xpo1 inhibitors for use in treating cancer |
| US11180473B2 (en) | 2020-03-27 | 2021-11-23 | Landos Biopharma, Inc. | PLXDC2 ligands |
| WO2021202745A1 (en) | 2020-03-31 | 2021-10-07 | Karyopharm Therapeutics Inc. | Treatment of covid-19 with a sine compound |
| US20230218644A1 (en) | 2020-04-16 | 2023-07-13 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
| WO2021252905A1 (en) | 2020-06-11 | 2021-12-16 | Karyopharm Therapeutics Inc. | Biomarkers for response to exportin-1 inhibitors in diffuse large b-cell lymphoma patients |
| WO2021252900A1 (en) | 2020-06-11 | 2021-12-16 | Karyopharm Therapeutics Inc. | Biomarkers for response to exportin-1 inhibitors in multiple myeloma patients |
| WO2021252874A1 (en) | 2020-06-11 | 2021-12-16 | Karyopharm Therapeutics Inc. | Xpo1 inhibitors for use in treating cancer |
| WO2022087218A1 (en) | 2020-10-21 | 2022-04-28 | Karyopharm Therapeutics Inc. | Crystalline form of selinexor |
| CN112679477B (zh) * | 2020-12-17 | 2021-10-26 | 佛山奕安赛医药科技有限公司 | 塞利尼索及其中间体的制备方法 |
| WO2022143779A1 (zh) * | 2020-12-29 | 2022-07-07 | 南京明德新药研发有限公司 | 含烯基类化合物及其应用 |
| WO2022232417A1 (en) | 2021-04-28 | 2022-11-03 | Karyopharm Therapeutics Inc. | Biomarkers for response to exportin-1 inhibitors in multiple myeloma patients |
| WO2022246065A1 (en) | 2021-05-19 | 2022-11-24 | Karyopharm Therapeutics Inc. | Calb1 biomarker in the treatment of de-differentiated liposarcoma using xpo1 inhibitors, such as selinexor |
| WO2023172855A2 (en) * | 2022-03-07 | 2023-09-14 | Kaohsiung Medical University | Methods for treating hepatitis b virus infection |
| CN116625976B (zh) * | 2023-04-10 | 2025-11-21 | 南京农业大学 | 一种微生物浓度的监测系统及方法 |
| CN116514773B (zh) * | 2023-04-24 | 2024-12-03 | 重庆汉佩生物科技有限公司 | 一种Verdinexor(KPT-335)及其盐酸盐的合成方法 |
| GB2643430A (en) * | 2024-08-14 | 2026-02-18 | Univ Cape Town | Nuclear transport inhibitors for anti-cancer combination therapy |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1017398A (en) | 1911-01-16 | 1912-02-13 | John E Folsom | Telegraph-key. |
| JPS5661360A (en) * | 1979-10-25 | 1981-05-26 | Teijin Ltd | 1-substituted imidazole derivative and its preparation |
| CS229934B2 (en) | 1981-07-07 | 1984-07-16 | Pfizer | Production method subst.indolylacryte acid derivative |
| KR840000529A (ko) | 1981-07-07 | 1984-02-25 | 콘스탄틴 루이스 클레멘트 | 인돌 유도체의 제조방법 |
| US4778796A (en) | 1985-07-19 | 1988-10-18 | Dainippon Pharmaceutical Co., Ltd. | ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same |
| IL97249A (en) * | 1990-02-23 | 1995-01-24 | Takeda Chemical Industries Ltd | Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or |
| JP3111321B2 (ja) | 1990-02-23 | 2000-11-20 | 武田薬品工業株式会社 | 縮合チアゾール化合物 |
| US5541213A (en) | 1993-06-24 | 1996-07-30 | Eisai Co., Ltd. | Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility |
| US5468353A (en) | 1994-05-05 | 1995-11-21 | Minnesota Mining And Manufacturing Company | Mist suppressant for solvent extraction metal electrowinning |
| AU4368996A (en) | 1994-11-23 | 1996-06-17 | Neurogen Corporation | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands |
| US20030018025A1 (en) | 1995-06-07 | 2003-01-23 | Neurogen Corporation, Corporation Of The State Of Delaware | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands |
| EP0858457A1 (de) | 1995-10-20 | 1998-08-19 | Dr. Karl Thomae GmbH | 5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung |
| CA2250002C (en) | 1996-04-04 | 2008-03-25 | Shionogi & Co., Ltd. | Cephem compounds and drugs containing the compounds |
| EP0913392B1 (en) | 1996-04-25 | 2003-07-02 | Nissan Chemical Industries, Limited | Ethylene derivatives and pest controlling agents |
| JP4054992B2 (ja) | 1996-04-25 | 2008-03-05 | 日産化学工業株式会社 | エチレン誘導体および有害生物防除剤 |
| DE19624659A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
| US5994398A (en) | 1996-12-11 | 1999-11-30 | Elan Pharmaceuticals, Inc. | Arylsulfonamides as phospholipase A2 inhibitors |
| JP4416198B2 (ja) | 1997-12-19 | 2010-02-17 | 武田薬品工業株式会社 | アニリド誘導体、その製造法および用途 |
| WO1999050264A1 (en) | 1998-03-30 | 1999-10-07 | Kyowa Hakko Kogyo Co., Ltd. | Quinazoline derivatives |
| US6743585B2 (en) | 1999-09-16 | 2004-06-01 | Agilent Technologies, Inc. | Methods for preparing conjugates |
| AR029803A1 (es) | 2000-02-21 | 2003-07-16 | Smithkline Beecham Plc | Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden |
| EP1335898B1 (en) | 2000-09-29 | 2005-11-23 | TopoTarget UK Limited | Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
| EP1429765A2 (en) | 2001-09-14 | 2004-06-23 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| AU2003287965A1 (en) | 2002-10-24 | 2004-05-13 | Carex Sa | Modulation of peroxisome proliferator activated receptors activity |
| DE10250743A1 (de) | 2002-10-31 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| NZ540381A (en) | 2002-11-01 | 2007-11-30 | Takeda Pharmaceutical | 5-membered aromatic heterocycle derivatives as prophylactic and therapeutic agents for treating neuropathy |
| JP4145230B2 (ja) | 2002-11-01 | 2008-09-03 | 武田薬品工業株式会社 | 神経障害の予防・治療剤 |
| ATE552253T1 (de) | 2002-11-08 | 2012-04-15 | Novartis Int Pharm Ltd | 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren |
| EP1599447A1 (en) | 2003-02-28 | 2005-11-30 | Galderma Research & Development, S.N.C. | Ligands that modulate lxr-type receptors |
| MY149038A (en) | 2004-05-26 | 2013-07-15 | Eisai R&D Man Co Ltd | Cinnamide compound |
| MX2007001634A (es) | 2004-08-11 | 2007-04-23 | Kyorin Seiyaku Kk | Nuevo derivado de acido amino benzoico ciclico. |
| WO2006019020A1 (ja) | 2004-08-16 | 2006-02-23 | Sankyo Company, Limited | 置換されたウレア化合物 |
| EP1849465A4 (en) | 2005-02-18 | 2008-12-24 | Takeda Pharmaceutical | AGENS TO CONTROL THE FUNCTION OF THE GPR34 RECEPTOR |
| US8637559B2 (en) | 2005-11-15 | 2014-01-28 | Otsuka Pharmaceutical Co., Ltd. | Oxazole compound and pharmaceutical composition |
| JP2007210929A (ja) | 2006-02-09 | 2007-08-23 | Sankyo Co Ltd | ウレア化合物を含有する医薬 |
| AR059955A1 (es) | 2006-03-09 | 2008-05-14 | Eisai R&D Man Co Ltd | Compuestos policiclicos no peptidicos, medicamentos que los contienen, y usos para prevenir o tratar enfermedades causadas por la produccion de beta amiloide |
| KR101495611B1 (ko) | 2006-04-07 | 2015-02-25 | 메틸진 인코포레이티드 | 히스톤 데아세틸라아제의 억제제 |
| CN101466687B (zh) | 2006-04-18 | 2012-04-11 | 日本化学医药株式会社 | 过氧化物酶体增殖剂激活受体δ的激活剂 |
| DE102006024024A1 (de) * | 2006-05-23 | 2007-11-29 | Bayer Healthcare Aktiengesellschaft | Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung |
| KR101130380B1 (ko) | 2006-06-13 | 2012-04-23 | 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 | 헤테로시클릭 비뉴클레오시드 화합물, 그의 제조방법, 약학적 조성물 및 항바이러스성 약제로서의 용도 |
| CN100503571C (zh) | 2006-07-12 | 2009-06-24 | 中国药科大学 | 四氢异喹啉类衍生物、其制备方法及其医药用途 |
| PL2054411T3 (pl) | 2006-07-27 | 2015-02-27 | Amorepacific Corp | Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne |
| AU2007292155B2 (en) | 2006-09-05 | 2012-11-01 | Kyowa Kirin Co., Ltd. | Imidazole derivative |
| EP1942104A1 (en) | 2006-12-20 | 2008-07-09 | sanofi-aventis | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals |
| EP1939180A1 (en) | 2006-12-20 | 2008-07-02 | sanofi-aventis | Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase |
| US7795457B2 (en) | 2007-02-26 | 2010-09-14 | Kosan Biosciences Incorporated | Carbamate compounds |
| EP2003118A1 (de) | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Zimtsäurederivate als Modulatoren des EP2-Rezeptors |
| US8106083B2 (en) | 2008-08-08 | 2012-01-31 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate HSP90 activity |
| CN102480969A (zh) | 2009-07-09 | 2012-05-30 | 科锐医疗有限公司 | 伤口愈合和瘢痕调制方法 |
| US8518968B2 (en) | 2009-12-04 | 2013-08-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hydrazone and diacyl hydrazine compounds and methods of use |
| CN103002742B (zh) | 2010-03-05 | 2016-07-13 | 卡尔约药物治疗公司 | 核转运调节剂及其应用 |
| JP6106605B2 (ja) | 2011-01-17 | 2017-04-05 | カリオファーム セラピューティクス，インコーポレイテッド | オレフィン含有核輸送調節剤およびその使用 |
| SMT201800171T1 (it) | 2011-07-29 | 2018-07-17 | Karyopharm Therapeutics Inc | Modulatori di trasporto nucleare contenenti idrazide e loro usi |
| US9428490B2 (en) | 2011-07-29 | 2016-08-30 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| WO2013020024A2 (en) | 2011-08-03 | 2013-02-07 | Karyopharm Therapeutics, Inc. | Maleimide compounds and methods of treatment |
| CA2872190C (en) | 2012-05-09 | 2024-06-25 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
| US10202366B2 (en) | 2013-03-15 | 2019-02-12 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using CRM1 inhibitors |
| US20160016916A1 (en) | 2013-03-15 | 2016-01-21 | Karyopharm Therapeutics Inc. | Exo Olefin-Containing Nuclear Transport Modulators and Uses Thereof |
| DK3492455T3 (da) | 2013-06-21 | 2023-08-14 | Karyopharm Therapeutics Inc | 1,2,4-triazoler som nukleare transportmodulatorer og anvendelse til behandling af specifikke former for cancer |
| WO2014205393A1 (en) | 2013-06-21 | 2014-12-24 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| WO2015073908A1 (en) | 2013-11-15 | 2015-05-21 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Method for selecting cancer treatment regimen |
| KR20170032244A (ko) | 2014-07-26 | 2017-03-22 | 선샤인 레이크 파르마 컴퍼니 리미티드 | Cdk 저해제로서 2-아미노-피리도[2,3-d]피리미딘-7(8h)-온 유도체 및 그 용도 |
| CN111484483B (zh) | 2014-08-15 | 2023-05-26 | 卡尔约药物治疗公司 | 赛灵克斯的多晶型物 |
| US10526295B2 (en) | 2015-12-31 | 2020-01-07 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| WO2017117535A1 (en) | 2015-12-31 | 2017-07-06 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| WO2017118940A1 (en) | 2016-01-08 | 2017-07-13 | Dr. Reddy's Laboratories Limited | Solid forms of selinexor and process for their preparation |
| JP6765198B2 (ja) | 2016-03-10 | 2020-10-07 | パナソニック株式会社 | 潜熱蓄熱材及びそれを用いる蓄熱システム |
| US11602530B2 (en) | 2016-11-28 | 2023-03-14 | Biogen Ma Inc. | CRM1 inhibitors for treating epilepsy |
| WO2018129227A1 (en) | 2017-01-05 | 2018-07-12 | Watson Laboratories Inc. | Novel crystalline forms of selinexor and process for their preparation |
| EP3808742A1 (en) | 2019-10-16 | 2021-04-21 | Sandoz AG | Polymorph of selinexor |
| WO2022087218A1 (en) | 2020-10-21 | 2022-04-28 | Karyopharm Therapeutics Inc. | Crystalline form of selinexor |
-
2012
- 2012-07-26 SM SM20180171T patent/SMT201800171T1/it unknown
- 2012-07-26 KR KR1020147005654A patent/KR102022716B1/ko active Active
- 2012-07-26 KR KR1020217019908A patent/KR20210083380A/ko not_active Ceased
- 2012-07-26 UA UAA201401886A patent/UA115532C2/uk unknown
- 2012-07-26 DK DK17189480.1T patent/DK3333164T3/da active
- 2012-07-26 PL PL12743846T patent/PL2736887T3/pl unknown
- 2012-07-26 DK DK12743846.3T patent/DK2736887T3/en active
- 2012-07-26 KR KR1020197011563A patent/KR102136768B1/ko active Active
- 2012-07-26 LT LTEP12743846.3T patent/LT2736887T/lt unknown
- 2012-07-26 TW TW101126934A patent/TWI574957B/zh active
- 2012-07-26 CN CN201910734865.3A patent/CN110372673B/zh active Active
- 2012-07-26 PT PT127438463T patent/PT2736887T/pt unknown
- 2012-07-26 PL PL17189480.1T patent/PL3333164T3/pl unknown
- 2012-07-26 EP EP12743846.3A patent/EP2736887B1/en active Active
- 2012-07-26 KR KR1020247013182A patent/KR20240060688A/ko not_active Ceased
- 2012-07-26 MX MX2017002113A patent/MX378433B/es unknown
- 2012-07-26 EP EP17189480.1A patent/EP3333164B1/en active Active
- 2012-07-26 GE GEAP201213396A patent/GEP201706616B/en unknown
- 2012-07-26 CN CN201610414957.XA patent/CN106083827B/zh active Active
- 2012-07-26 ES ES12743846.3T patent/ES2655645T3/es active Active
- 2012-07-26 WO PCT/US2012/048319 patent/WO2013019548A1/en not_active Ceased
- 2012-07-26 CN CN201910730981.8A patent/CN110372672B/zh active Active
- 2012-07-26 AR ARP120102724A patent/AR087342A1/es active IP Right Grant
- 2012-07-26 JP JP2014522997A patent/JP6005740B2/ja active Active
- 2012-07-26 EP EP23162715.9A patent/EP4234545A3/en active Pending
- 2012-07-26 HU HUE12743846A patent/HUE036058T2/hu unknown
- 2012-07-26 PE PE2014000139A patent/PE20141170A1/es active IP Right Grant
- 2012-07-26 BR BR112014001934-7A patent/BR112014001934B1/pt active IP Right Grant
- 2012-07-26 SI SI201231147T patent/SI2736887T1/en unknown
- 2012-07-26 KR KR1020207020507A patent/KR20200088518A/ko not_active Ceased
- 2012-07-26 KR KR1020257000206A patent/KR20250008805A/ko active Pending
- 2012-07-26 HR HRP20180014TT patent/HRP20180014T1/hr unknown
- 2012-07-26 CN CN201280047939.2A patent/CN103874690B/zh active Active
- 2012-07-26 RS RS20171350A patent/RS56823B1/sr unknown
- 2012-07-26 EA EA201490407A patent/EA201490407A1/ru unknown
- 2012-07-26 AU AU2012290454A patent/AU2012290454B2/en active Active
- 2012-07-26 ES ES17189480T patent/ES2954991T3/es active Active
- 2012-07-26 CN CN202311190454.5A patent/CN117229268A/zh active Pending
- 2012-07-26 CA CA2842362A patent/CA2842362C/en active Active
- 2012-07-26 MX MX2014001181A patent/MX349712B/es active IP Right Grant
- 2012-07-26 KR KR1020237008529A patent/KR20230042129A/ko not_active Ceased
- 2012-07-29 US US14/235,306 patent/US9079865B2/en active Active
-
2014
- 2014-01-29 CL CL2014000225A patent/CL2014000225A1/es unknown
- 2014-02-18 ZA ZA2014/01223A patent/ZA201401223B/en unknown
- 2014-02-27 CO CO14041777A patent/CO6960539A2/es active IP Right Grant
- 2014-03-19 US US14/219,638 patent/US8999996B2/en active Active
-
2015
- 2015-05-11 CL CL2015001257A patent/CL2015001257A1/es unknown
- 2015-06-10 US US14/735,853 patent/US9206158B2/en active Active
- 2015-11-13 US US14/940,310 patent/US9714226B2/en active Active
-
2016
- 2016-08-04 AU AU2016210682A patent/AU2016210682B2/en active Active
- 2016-09-07 JP JP2016174614A patent/JP6309057B2/ja active Active
-
2017
- 2017-06-21 US US15/629,307 patent/US10173987B2/en active Active
-
2018
- 2018-01-17 CY CY20181100059T patent/CY1119783T1/el unknown
- 2018-03-13 JP JP2018044974A patent/JP6675431B2/ja active Active
- 2018-04-02 ME MEP-2017-303A patent/ME02936B/me unknown
- 2018-04-06 AU AU2018202441A patent/AU2018202441B2/en active Active
- 2018-11-28 US US16/203,181 patent/US10544108B2/en active Active
-
2019
- 2019-11-26 US US16/696,702 patent/US11034660B2/en active Active
-
2020
- 2020-05-12 AU AU2020203121A patent/AU2020203121B2/en active Active
-
2021
- 2021-05-14 US US17/321,029 patent/US11787771B2/en active Active
- 2021-07-30 LT LTPA2021007C patent/LTC2736887I2/lt unknown
- 2021-07-30 NL NL301119C patent/NL301119I2/nl unknown
- 2021-08-18 LU LU00219C patent/LUC00219I2/fr unknown
- 2021-08-26 HU HUS2100030C patent/HUS2100030I1/hu unknown
- 2021-09-06 NO NO2021033C patent/NO2021033I1/no unknown
- 2021-09-15 FR FR21C1042C patent/FR21C1042I2/fr active Active
- 2021-09-22 CY CY2021028C patent/CY2021028I2/el unknown
-
2022
- 2022-05-16 AU AU2022203265A patent/AU2022203265A1/en not_active Abandoned
-
2023
- 2023-09-11 US US18/244,659 patent/US12291508B2/en active Active
-
2024
- 2024-05-01 AU AU2024202868A patent/AU2024202868A1/en active Pending
-
2025
- 2025-03-10 US US19/075,233 patent/US20260062391A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014521652A5 (https=) | ||
| ME02936B (me) | Modulatori transporta u- i iz-jezgra, koji sadrže hidrazid, i njihove upotrebe | |
| RU2750148C1 (ru) | Соединения, пригодные для использования в качестве ингибиторов atr киназы | |
| JP2009507909A5 (https=) | ||
| RU2650895C2 (ru) | Соединения замещенных пиразолонов и способы использования | |
| JP6942380B2 (ja) | 新規イソインドリン誘導体、その医薬組成物および使用 | |
| RU2725979C2 (ru) | ИМИДАЗО[1,2-а]ПИРАЗИН-1-ИЛ-БЕНЗАМИДЫ ДЛЯ ЛЕЧЕНИЯ СПИНАЛЬНОЙ МЫШЕЧНОЙ АТРОФИИ | |
| US10004755B2 (en) | Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity | |
| AU2015207757B2 (en) | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | |
| CN113956238B (zh) | 一种蛋白激酶抑制剂及其制备方法和医药用途 | |
| JP2010540509A5 (https=) | ||
| CN112745335B (zh) | 一种三并杂环化合物及其用途 | |
| CN112707905B (zh) | 一种三并杂环化合物及其制备方法和用途 | |
| JP2012524053A5 (https=) | ||
| RU2007105350A (ru) | 3-(гетероарилокси)-2-алкил-1-азабициклоалкильные производные, как лиганды альфа-7-nachr (никотиновых ацетилхолиновых рецепторов), предназначенные для лечения заболеваний центральной нервной системы | |
| JP2018533611A5 (https=) | ||
| JP2019529484A5 (https=) | ||
| JP2012530703A5 (https=) | ||
| JP2015511638A5 (https=) | ||
| JP7728287B2 (ja) | Ｃｄｋ６／ｄｙｒｋ２二重標的阻害剤およびその製造方法と応用 | |
| JP2017503813A5 (https=) | ||
| RU2015124002A (ru) | Соединения, применяемые в качестве ингибиторов индоламин-2,3-диоксигеназы | |
| US10577362B2 (en) | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases | |
| JP2015524412A5 (https=) | ||
| RU2017101829A (ru) | Пиразоловые соединения в качестве модуляторов fshr и пути их применения |